PSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population

Shizhi Wang1, Shenshen Wu2, Haixia Zhu2, Bo Ding3, Yunlang Cai3, Jing Ni4, Qiang Wu4, Qingtai Meng4, Xin Zhang1, Chengcheng Zhang1, Xiaobo Li1, Meilin Wang5, Rui Chen1, Hua Jin2 & Zhengdong Zhang5,6

Recently, three genome-wide association studies have identified the PSCA (prostate stem cell antigen) rs2294008 polymorphism (C \( \rightarrow \) T) associated with susceptibility to gastric cancer, bladder cancer, and duodenal ulcers, highlighting its critical role in disease pathogenesis. Given PSCA is reported to be overexpressed in cervical cancer and the rs2294008 can influence PSCA transcription, we aimed to determine the role of rs2294008 in susceptibility to cervical cancer. The genotyping was performed in the 1126 cases and 1237 controls. Our results showed the rs2294008 TT genotype significantly associated with a reduced risk of cervical cancer (adjusted OR = 0.55, 95% CI = 0.38–0.79; recessive model). Stratified analyses revealed that the association was restricted to the subgroups of age > 49 years, parity \( \leq \) 1, abortion and early-stage cervical cancer. Immunohistochemistry assay showed the individuals carrying the TT genotype having lower PSCA expression than those with CC/CT genotypes. In summary, the PSCA rs2294008 polymorphism may serve as a biomarker of cervical cancer, particularly of early-stage cervical cancer.
PSCA expression was associated with reduced cell proliferation of bladder cancer in vitro and in vivo, and moreover with activation of genes of downstream of the IFNα/β receptor. In contrast, reduced PSCA expression is observed in gastric, gallbladder, and head-and-neck squamous cell cancers. Sakamoto et al. found that PSCA participated in gastric cell-proliferation inhibition and cell death activation, acting as a tumor suppressor gene. The discrepancy reflects the complexity of PSCA regulation, involving pro-tumorigenic and anti-tumorigenic functions in various contexts. As to the possible role of PSCA in cervical cancer, Liu et al. reported that PSCA was highly expressed in cervical cancer than in adjacent normal cervix, and positively correlated with invasion of cervical cancer, implying an oncogenic role in cervical carcinogenesis.

The SNP rs2294008 polymorphism (C > T, Met1Thr), located in the translation starting site of PSCA gene, can lead to an alternative splice variant of PSCA with an additional fragment of 9 amino acids at the N-terminal portion and change protein localization from cytoplasm to cell surface. After the first reported by Sakamoto et al., some other studies performed in China, Japan and European populations have validated the link between the polymorphism and gastric cancer risk. Besides gastric cancer, two other GWAS have identified its association with bladder cancer and duodenal ulcers susceptibility in US and Japan populations, respectively. The SNP has also shown to correlate with susceptibility to other solid tumors, including esophagus and breast cancers. Taking into account the potential oncogenic role of PSCA in cervical cancer and the attractive statistical significance of the rs2294008 polymorphism among the three GWAS, we aimed to determine the association of the rs2294008 polymorphism with risk of cervical cancer in a Chinese population.

Materials and Methods

Ethics statement. The study was approved by the institutional review board of Southeast University. Each subject signed an informed consent. The research protocol was carried out in accordance with the approved guidelines.

Study subjects. The study enrolled two independent sets of subjects. The test set comprised of 571 case patients and 657 healthy controls recruited from hospitals in Nanjing and Wuxi cities between January 2007 and December 2010. The validation set comprised of 555 case and 580 controls recruited from hospitals in Nantong City between January 2009 and December 2013. All patients were newly diagnosed with histologically confirmed cervical cancer. Those who had metastasized cancers from other origin or preoperative chemo/radio-therapy were excluded. All controls were genetically unrelated to the cases and recruited from those who were seeking for health care in the same hospitals.

Genotyping. Genomic DNA of the test set and controls of the validation set was extracted from the peripheral blood lymphocytes. The sections of formalin-fixed paraffin-embedded (FFPE) tissues were used for DNA extraction for the patients in the validation set, due to lack of blood samples. The genotypes of the rs2294008 polymorphism were determined by TaqMan allelic discrimination method equipped with ABI 7900HT Real Time PCR System. Quality control for the genotyping was achieved by including in each amplification a negative PCR control sample and three positive control samples for each genotype. At least 10% of the samples were randomly selected for genotyping confirmation, and the results were 100% concordant.

Immunohistochemistry (IHC). IHC for PSCA was performed on representative paraffin sections of primary cervical cancer tissues. The procedure of immunostaining has been described in our previous publication. Series of paraffin sections of specimens were incubated with polyclonal rabbit anti-PSCA antibody (BA1694, BOSTER, Wuhan, China) overnight at 4°C, and 3,3′-diaminobenzidine (DAB; Zhongshan Biotech, Beijing, China) was used to produce a brown precipitate. The evaluation of PSCA expression was made in a blind fashion by two independent pathologists simultaneously. The final PSCA staining score was calculated by multiplying the intensity and the percentage of positive cells, and categorized as follows: 3, negative or weak; ≥6, strong.

Statistical analysis. A goodness-of-fit chi-square test ($\chi^2$ test) was applied to test the Hardy-Weinberg equilibrium (HWE) of the controls’ genotype frequencies. Differences between cases and controls in demographic characteristics and frequencies of allele and genotype of rs2294008 were evaluated by $t$ test (for continuous variables) or by $\chi^2$ test (for categorical variables). The magnitude of the association of rs2294008 variants in each group was estimated using odds ratios (ORs) and 95% confidence intervals (CIs). For all tests, a two-sided $P$-value < 0.05 was considered statistically significant.

Results

Demographic and clinical characteristics of the study subjects. The demographic and clinical characteristics of the cases and controls are shown in Table 1. There were no differences in the distribution of age and abortion between the cases and controls in both test and validation sets ($P = 0.726$ and $0.798$, respectively); abortion, $P = 0.565$ and 0.942, respectively). More subjects with higher parity (>2) were observed in the cervical cancer patients than in the controls in both test (41.7% vs. 24.8%) and validation (45.4% vs. 17.6) sets (all $P < 0.001$). More subjects with postmenopausal status were observed in the cervical cancer patients than in the controls in the test set (44.0% vs. 21.1%), whereas more subjects with premenopausal status were observed in the cervical cancer patients in the validation set (52.8% vs. 42.6%) (all $P < 0.001$). The proportion of patients with T1 stage in the validation set was similar with that in the test set (68% vs. 65%). The patients with T2 were more in the validation set than in the test set (34.4% vs. 25.8%), whereas the patients with T3 or T4 were less in the validation set than in the test set (0.6 vs. 6.2%).
The genotype frequencies of rs2294008 polymorphism in the control group of both test and validation sets did not deviate significantly from those expected under Hardy-Weinberg equilibrium model (P = 0.672 and 0.105 for the test and validation set, respectively). We further combined the two sets for enlargement of statistic power, and found statistically significant differences in the distribution of the rs2294008 genotypes and alleles between the cases and controls (P = 0.002 and 0.005, respectively; Table 2). When the CC genotype used as the reference, the heterozygous genotype CT was not associated with risk of cervical cancer (adjusted OR = 0.91, 95% CI = 0.77–1.09), whereas the homozygous mutant TT genotype was associated with a significantly reduced risk of cervical cancer (adjusted OR = 0.53, 95% CI = 0.37–0.77). When a recessive genetic model was employed, the TT genotype conferred a predominantly decreased risk of cervical cancer whatsoever adjusting for confounder factors (adjusted OR = 0.55, 95% CI = 0.38–0.79; Table 2).

### Table 1. Frequency distribution of select variables in cervical cancer cases and controls. *Some cases lack information of selected variables. **Other histological types, such as cervical choriocarcinoma.

| Variables          | Test set          | Validation set       |
|--------------------|-------------------|----------------------|
| Age, year (mean ± SD) | n = 571 (%)       | n = 657 (%)          |
| Parity             |                   |                      |
| 0–1                | 324 (58.3)        | 446 (75.2)           |
| ≥2                 | 232 (41.7)        | 147 (24.8)           |
| Abortion           |                   |                      |
| No                 | 158 (29.5)        | 156 (28.0)           |
| Yes                | 377 (70.5)        | 402 (72.0)           |
| Menopausal status  |                   |                      |
| Premenopausal      | 306 (56.0)        | 476 (78.9)           |
| Postmenopausal     | 240 (44.0)        | 127 (21.1)           |
| Histologic types   |                   |                      |
| Squamous cell carcinoma | 538 (94.2) | 506 (91.2)          |
| Adenocarcinomas    | 24 (4.2)          | 28 (5.1)             |
| Adenosquamous carcinoma | 4 (0.7)  | 12 (2.2)            |
| Others             | 5 (0.9)           | 9 (1.5)              |
| Depth of invasion  |                   |                      |
| I                  | 383 (68)          | 357 (65.0)           |
| II                 | 145 (25.8)        | 189 (34.4)           |
| III                | 28 (5.0)          | 2 (0.4)              |
| IV                 | 7 (1.2)           | 1 (0.2)              |

### Table 2. Association between PSCA SNP rs2294008 and risk of cervical cancer. *Adjusted for age, parity and menopausal status in logistic regression model.

| Genotype | Combined set | P       | OR (95% CI)* |
|----------|--------------|---------|-------------|
|          | Test set     | Validation set     |
|          | Cases (n = 1126 (%)) | Controls (n = 1237 (%)) |       |     |
| CC       | 609 (54.1) | 618 (50.0) | 0.002 | 1.00 (Ref.) |
| CT       | 469 (41.6) | 527 (42.6) | 0.91 | 0.77–1.09 |
| TT       | 48 (4.3)   | 92 (7.4)   | 0.53 | 0.37–0.77 |
| T allele |             |           | 0.005 |     |
| CC/CT    | 1078 (95.7) | 1145 (92.6) | 0.001 | 1.00 (Ref.) |
| TT       | 48 (4.3)   | 92 (7.4)   | 0.55 | 0.38–0.79 |

**PSCA rs2294008 polymorphism and cervical cancer susceptibility.** The genotype frequencies of rs2294008 polymorphism in the control group of both test and validation sets did not deviate significantly from those expected under Hardy-Weinberg equilibrium model (P = 0.672 and 0.105 for the test and validation set, respectively). We further combined the two sets for enlargement of statistic power, and found statistically significant differences in the distribution of the rs2294008 genotypes and alleles between the cases and controls (P = 0.002 and 0.005, respectively; Table 2). When the CC genotype used as the reference, the heterozygous genotype CT was not associated with risk of cervical cancer (adjusted OR = 0.91, 95% CI = 0.77–1.09), whereas the homozygous mutant TT genotype was associated with a significantly reduced risk of cervical cancer (adjusted OR = 0.53, 95% CI = 0.37–0.77). When a recessive genetic model was employed, the TT genotype conferred a predominantly decreased risk of cervical cancer whatsoever adjusting for confounder factors (adjusted OR = 0.55, 95% CI = 0.38–0.79; Table 2).

**Stratified analysis of PSCA rs2294008 polymorphism and cervical cancer risk.** In the stratified analyses, the TT genotype conferred a predominantly decreased risk of cervical cancer in both test and validation sets (adjusted OR = 0.54, 95% CI = 0.33–0.89, and 0.56, 0.34–0.98 for the test and validation sets, respectively; Table 3). Further stratified analyses by demographic characteristics revealed that the association between the rs2294008 TT genotype and cervical cancer risk was predominant in both pre- and post-menopausal status (adjusted OR = 0.60, 95% CI = 0.37–0.97, and 0.50, 0.29–0.87 for premenopausal and postmenopausal status, respectively), but restricted to the subgroups of age > 49 years, parity ≤ 1, and abortion (adjusted OR = 0.42, 95% CI = 0.25–0.72 for age > 49 years; 0.63, 0.40–0.99 for parity ≤ 1; and 0.42, 0.26–0.69 for abortion; Table 3).
We also evaluated the relationship between the rs2294008 variants and invasion of cervical cancer, and found that the polymorphism was significantly associated with early-stage cervical cancer (adjusted OR = 0.53, 95% CI = 0.34–0.81; Table 3).

Table 3. Stratified analysis of the SNP rs2294008 genotypes associated with cervical cancer risk by selected variables. *Adjusted for age, parity, and menopausal status in logistic regression model.

| Variables          | Genotypes (cases/controls) | P     | Adjusted OR (95% CI)* |
|--------------------|-----------------------------|-------|-----------------------|
|                    | CC/CT                       | TT    |                       |
| Set                |                             |       |                       |
| Test               | 545/604                     | 26/53 | 0.012                 | 0.54 (0.33–0.89) |
| Validation         | 533/541                     | 22/39 | 0.039                 | 0.56 (0.34–0.98) |
| Age (years)        |                             |       |                       |
| ≤ 49               | 584/638                     | 27/44 | 0.109                 | 0.72 (0.44–1.19) |
| > 49               | 494/507                     | 21/48 | 0.002                 | 0.42 (0.25–0.72) |
| Parity             |                             |       |                       |
| 0–1                | 592/834                     | 29/67 | 0.029                 | 0.63 (0.40–0.99) |
| ≥ 2                | 461/228                     | 18/16 | 0.093                 | 0.57 (0.28–1.14) |
| Abortion           |                             |       |                       |
| No                 | 350/345                     | 23/26 | 0.643                 | 0.82 (0.46–1.49) |
| Yes                | 679/676                     | 24/58 | <0.001                | 0.42 (0.26–0.69) |
| Menopausal status  |                             |       |                       |
| Premenopausal      | 570/657                     | 27/52 | 0.034                 | 0.60 (0.37–0.97) |
| Postmenopausal     | 479/404                     | 21/37 | 0.008                 | 0.50 (0.29–0.87) |
| Depth of invasion  |                             |       |                       |
| I                  | 710/1145                    | 30/92 | 0.53 (0.34–0.81)      |
| II                 | 317/1145                    | 17/92 | 0.67 (0.39–1.15)      |
| III/IV             | 37/1145                     | 1/92  | 0.33 (0.05–2.46)      |

rs2294008 polymorphism and PSCA protein expression. We then evaluated the association between the rs2294008 and PSCA protein expression in 50 cervical cancer tissues by IHC assay. We first genotyped rs2294008 in a total of 100 cervical cancer patients which have additional paraffin sections for IHC staining. The frequency distribution of CC, CT, and TT was 55, 39, and 6, respectively. Because the CC genotype was the wild genotype carried by the most cases and the TT was the homozygous mutant genotype carried by the least cases, we chose 25 (a half of 50 cases) cases carrying the CC genotypes, and kept all 6 cases carrying the TT genotypes. Finally, we chose 19 cases carrying the CT genotypes, which making the ratio between the CC and CT/TT genotypes 1:1.

The representative IHC staining of PSCA in cervical cancer tissues with different rs2294008 genotypes was shown in Fig. 1 (upper panel). PSCA was expressed in the cytoplasm. There was a significant difference in cytoplasm staining of tissues between the patients with TT genotype and those with CC/CT genotypes (average staining score: 1.50 versus 5.32 for TT and CC/CT genotypes, respectively, \( P = 0.004 \); Fig. 1 bottom).

Discussion

PSCA rs2294008 polymorphism has been identified by three GWAS in association with gastric cancer, bladder cancer and duodenal ulcer, highlighting its important role in disease pathogenesis. After its first reported by Sakamoto et al.3, several studies performed in Asian and Caucasian populations have validated its significant association with gastric and bladder cancer susceptibility. Furthermore, a number of studies have evaluated the relationship between this polymorphism and other solid tumors, including prostate, breast, colorectal, pancreatic, and esophageal tumors. To date, there is no report regarding the rs2294008 polymorphism in relation to susceptibility to cervical cancer. In the present study, we demonstrated that the homozygous variant TT genotype conferred a significantly reduced risk of cervical cancer compared with the wild-type containing genotypes. Stratified analysis showed that the association was restricted to the subgroups of no abortion and premenopausal status. In addition, the polymorphism correlated to the early-stage cervical cancer.

PSCA was considered to serve as tumor suppressor gene in gastric cancer by influencing gastric cell-proliferation inhibition and cell death activation5. The rs2294008 polymorphism (C to T transition), within the translation starting site of PSCA, could lead to a significant reduction of transcriptional activity. Therefore, a decreased PSCA expression associated with the T allele could render an individual more susceptible to develop GC. In contrast to the role of PSCA in gastric cancer, there was evidence demonstrated that PSCA was overexpressed in bladder cancer and the T allele was linked to an increased PSCA mRNA expression in both bladder tumor and adjacent normal tissues10,23. The discrepancy reflects that the regulation and biological function of PSCA is complex and depends on the cell-type context. The study on the expression and function of PSCA in cervical cancer is limited. A study conducted by Liu et al.8 displayed that PSCA was upregulated in cervical cancer and its expression level was in relation to the invasion of cervical cancer,
indicating an oncogenic role in cervical cancer. In this study, we found that the homozygous variant TT genotype was relevant to a decreased risk of cervical cancer (OR = 0.55, 95% CI = 0.38–0.79) in the combined set. Intriguingly, the magnitude of association of the T allele with reduced risk of cervical cancer was comparable with that observed in esophageal adenocarcinoma and squamous cell carcinoma (OR, 0.5; 95% CI: 0.3–0.9 and OR, 0.4; 95% CI: 0.2–0.9, respectively)\textsuperscript{19}. Furthermore, the individuals with TT genotype had significantly reduced PSCA protein expression compared with those with CC/CT genotypes. We propose that the variant T allele may result in a decreased transcriptional activity of \textit{PSCA} and thus protein expression in cervical cancer, and consequently conferred reduced cervical cancer susceptibility. Further functional studies characterizing the role of PSCA in cervical cancer and the effect of the rs2294008 polymorphism on PSCA expression are warranted.

Apart from rs2294008, there are other loci at the PSCA gene such as rs2976392 and rs2978974 to be identified in association with cervical cancer susceptibility. In 2008, Sakamoto \textit{et al.}\textsuperscript{3} firstly identified a significant association between rs2976392 locating in the intron of \textit{PSCA} and diffuse-type gastric cancer. Because rs2294008 can modulate transcriptional activity of the upstream region of PSCA and has a strong LD with rs2976392 ($r^2 = 0.995$, $D' = 0.999$), they proposed that the functional SNP is the former, rs2294008. After Wu \textit{et al.}\textsuperscript{4} reported a significant association between the rs2294008 and bladder cancer in 2009, Fu \textit{et al.}\textsuperscript{23} performed a fine-mapping study of the 8q24.3, where PSCA maps, by imputing 642 SNPs within 100 kb of rs2294008 in addition to 33 other markers. A multivariable logistic regression model adjusted for rs2294008 revealed a unique signal, rs2978974 ($r^2 = 0.02$, $D' = 0.19$ with rs2294008), which locates 10 kb upstream of rs2294008. Although the non-risk allele G of rs2978974 interacted strongly with nuclear proteins which implying a regulatory function, rs2978974 was not associated with \textit{PSCA} mRNA expression. On the contrary, the T risk allele of rs2294008 was associated with increased \textit{PSCA} mRNA expression, suggesting that both variants may be important for bladder cancer susceptibility, possibly through different mechanisms. Fu \textit{et al.}\textsuperscript{23} also found a significant multiplicative interaction between rs2294008 and rs2978974, implying a joint effect of two SNPs on cancer susceptibility. Therefore, the association between rs2978974 joint with or without rs2294008 and cervical cancer susceptibility deserves further investigation.

Some limitations in this study should be addressed. First, the information on human papillomavirus (HPV) infection in subjects is missing. HPV is the necessary cause of cervical cancer\textsuperscript{24}. However, HPV is not the necessity in diagnose of cervical cancer (NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 2.2015). In addition, HPV screening is expensive and requires a handsome amount of money to establish a high-standard testing system with well-trained cytologists who can accurately identify the cells scraped from the cervix, which limiting its wide application in population screening and physical examination in China\textsuperscript{25}. Second, the functionality of PSCA in cervical carcinogenesis and the underlying molecular mechanism of rs2294008 modulating cervical cancer susceptibility need further evaluation. Third, we compared the distribution of rs2294008 genotypes between the cases with FFPE tissues and the controls with blood samples in the validation set. Genotyping DNA from FFPE tissues may be inaccurate due to FFPE storage, genetic aberrations, and/or insufficient DNA extraction\textsuperscript{26}. Recently, Hertz \textit{et al.} performed a study to investigate the genotyping concordance in DNA extracted from FFPE breast tumor and whole blood, and found that no- and discordant-call rates were
below concerning thresholds, and most SNPs could be accurately genotyped from FFPE tissues\(^2\). In the present study, we compared the distribution of rs2294008 genotypes between the DNA extracted from blood samples (571) and DNA from FFPE tissues (355) using \(\chi^2\) test. The resultant \(P\) value was 0.882, indicating no significant difference in frequency distribution of rs2294008 genotypes between the two sources of DNA. Finally, there is no IHC staining of PSCA in the controls due to lack of normal tissues adjacent to cervical tumors, which making us unable to compare the IHC staining of PSCA of cervical tumors with that of controls. It is warranted to collect normal tissues adjacent to tumors as much as possible for the future gene expression analyses between the tumors and controls.

In conclusion, the PSCA rs2294008 polymorphism was associated with a reduced risk of cervical cancer in a Chinese population. Further studies with large samples at different geographic areas and ethnic groups are warranted to confirm and extend our findings.

### References

1. Manolio, T. A. Cohort studies and the genetics of complex disease. *Nat Genet* **41**, 5–6 (2009).
2. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* **42**, D1001–1006 (2014).
3. Sakamoto, H. et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. *Nat Genet* **40**, 730–740 (2008).
4. Wu, X. et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. *Nat Genet* **41**, 991–995 (2009).
5. Tanikawa, C. et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* **44**, 430–434, S431–432 (2012).
6. Reiter, R. E. et al. Prostate stem cell antigen variant: a cell surface marker overexpressed in prostate cancer. *Proc Natl Acad Sci USA* **95**, 1735–1740 (1998).
7. Bahrenberg, G., Brauers, A., Joost, H. G. & Jakse, G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. *Biochem Biophys Res Commun* **275**, 783–788 (2000).
8. Liu, W. K., Jiang, X. Y. & Zhang, Z. X. Expression of PSCA, PIWIL1 and TBX2 in correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. *Arch Virol* **155**, 657–663 (2010).
9. Marra, E. et al. Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. *BMC Cancer* **10**, 129 (2010).
10. Amara, N. et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. *Cancer Res* **61**, 4660–4665 (2001).
11. Argani, P. et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. *Cancer Res* **61**, 4320–4324 (2001).
12. Ono, H. et al. Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. *Genes Chromosomes Cancer* **51**, 30–41 (2012).
13. de Nooij-van Dalen, A. G. et al. Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. *Int J Cancer* **103**, 768–774 (2003).
14. Saeki, N., Gu, J., Yoshida, T. & Wu, X. Prostate stem cell antigen: a Jekyll and Hyde molecule? *Clin Cancer Res* **16**, 3533–3538 (2010).
15. Wu, C. et al. Two genetic variants in prostate stem cell antigen and gastric cancer susceptibility in a Chinese population. *Mol Carcinog* **48**, 1131–1138 (2009).
16. Lu, Y. et al. Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. *Int J Cancer* **127**, 2183–2189 (2010).
17. Zheng, Z. et al. Polymorphisms in prostate stem cell antigen gene rs229408 increase gastric cancer risk in Chinese. *Mol Carcinog* **50**, 353–358 (2011).
18. Matsuo, K. et al. Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. *Int J Cancer* **125**, 1961–1964 (2009).
19. Lochhead, P. et al. Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. *Gastroenterology* **140**, 435–441 (2011).
20. Sala, N. et al. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: results from the EPIC-EURGAST study. *Int J Cancer* **130**, 2417–2427 (2012).
21. Kim, S. Y. et al. Prostate stem cell antigen single nucleotide polymorphisms influence risk of estrogen receptor negative breast cancer in Korean females. *Asian Pac J Cancer Prev* **13**, 41–48 (2012).
22. Wu, D. M. et al. Genetic variations in the SMAD4 gene and gastric cancer susceptibility. *World J Gastroenterol* **16**, 5635–5641 (2010).
23. Fu, Y. P. et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. *Proc Natl Acad Sci USA* **109**, 4974–4979 (2012).
24. Crossbie, E. J., Einstein, M. H., Franceschi, S. & Kitchener, H. C. Human papillomavirus and cervical cancer. *Lancet* **382**, 889–899 (2013).
25. Wen, C. China’s plans to curb cervical cancer. *Lancet Oncol* **6**, 139–141 (2005).
26. Hertz, D. L. et al. Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. *Mol Oncol* **9**, 1868–1876 (2015).

### Acknowledgements

This study was partly supported by National Natural Science Foundation of China (81302502), National Science Foundation of Jiangsu Province (BK201130641), Specialized Research Fund for the Doctoral Program of Higher education of China (20130092120063), the Fundamental Research Funds for the Central Universities and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine).

### Author Contributions

R.C., H.J. and Z.Z. conceived and designed the experiments. Sz.W., Sz.W. and X.L. performed the experiments. Q.M., C.Z., X.Z. and M.W. analyzed the data. H.J., H.Z., Y.C., B.D., Q.W. and J.N. contributed reagents/materials/analysis tools. Sz.W. wrote the paper.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, S. et al. PSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population. Sci. Rep. 6, 23465; doi: 10.1038/srep23465 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/